Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Iterum Therapeutics stock

Own Iterum Therapeutics stock in just a few minutes.

Iterum Therapeutics plc is a biotechnology business based in the US. Iterum Therapeutics shares (ITRM) are listed on the NASDAQ and all prices are listed in US Dollars. Iterum Therapeutics employs 7 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Iterum Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ITRM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Iterum Therapeutics share price

Use our graph to track the performance of ITRM stocks over time.

Iterum Therapeutics shares at a glance

Information last updated 2021-04-29.
52-week range$0.45 - $4.70
50-day moving average $1.39
200-day moving average $1.20
Wall St. target price$2.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-7.05

Buy Iterum Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Iterum Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Iterum Therapeutics financials

Gross profit TTM $37,000
Return on assets TTM -68.6%
Return on equity TTM 0%
Profit margin 0%
Book value $1.71
Market capitalisation $207.9 million

TTM: trailing 12 months

Shorting Iterum Therapeutics shares

There are currently 4.5 million Iterum Therapeutics shares held short by investors – that's known as Iterum Therapeutics's "short interest". This figure is 14.5% up from 4.0 million last month.

There are a few different ways that this level of interest in shorting Iterum Therapeutics shares can be evaluated.

Iterum Therapeutics's "short interest ratio" (SIR)

Iterum Therapeutics's "short interest ratio" (SIR) is the quantity of Iterum Therapeutics shares currently shorted divided by the average quantity of Iterum Therapeutics shares traded daily (recently around 14.2 million). Iterum Therapeutics's SIR currently stands at 0.32. In other words for every 100,000 Iterum Therapeutics shares traded daily on the market, roughly 320 shares are currently held short.

However Iterum Therapeutics's short interest can also be evaluated against the total number of Iterum Therapeutics shares, or, against the total number of tradable Iterum Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Iterum Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Iterum Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.032% of the tradable shares (for every 100,000 tradable Iterum Therapeutics shares, roughly 32 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Iterum Therapeutics.

Find out more about how you can short Iterum Therapeutics stock.

Iterum Therapeutics share dividends

We're not expecting Iterum Therapeutics to pay a dividend over the next 12 months.

Iterum Therapeutics share price volatility

Over the last 12 months, Iterum Therapeutics's shares have ranged in value from as little as $0.451 up to $4.7. A popular way to gauge a stock's volatility is its "beta".

ITRM.US volatility(beta: 1.34)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Iterum Therapeutics's is 1.3397. This would suggest that Iterum Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Iterum Therapeutics overview

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland. .

Frequently asked questions

What percentage of Iterum Therapeutics is owned by insiders or institutions?
Currently 0.606% of Iterum Therapeutics shares are held by insiders and 9.13% by institutions.
How many people work for Iterum Therapeutics?
Latest data suggests 7 work at Iterum Therapeutics.
When does the fiscal year end for Iterum Therapeutics?
Iterum Therapeutics's fiscal year ends in December.
Where is Iterum Therapeutics based?
Iterum Therapeutics's address is: Harcourt Centre, Dublin, Ireland, 2
What is Iterum Therapeutics's ISIN number?
Iterum Therapeutics's international securities identification number is: IE00BF3W0Q35
What is Iterum Therapeutics's CUSIP number?
Iterum Therapeutics's Committee on Uniform Securities Identification Procedures number is: G6333L101

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site